- European markets recover from corrections, mostly due to Donald's Trump ease of rhetoric towards China
- European pharmaceuticals producers make a bid to circumvent tariffs
- Automakers stocks up despite difficult situation
- France's new government forming puts some of the investors at ease
- European markets recover from corrections, mostly due to Donald's Trump ease of rhetoric towards China
- European pharmaceuticals producers make a bid to circumvent tariffs
- Automakers stocks up despite difficult situation
- France's new government forming puts some of the investors at ease
The week on European stock exchanges clearly begins with gains. Most major indices in Western Europe are experiencing a solid rebound, which can be interpreted as a corrective rise following last week's declines. The German DAX, along with CAC40 and the Italian FTSE MIB, gains on opening by an average of over 1%.
Despite the lack of significant macroeconomic publications, today's session brings large price movements. It is evident that investors in Europe are again reacting mainly to events from across the ocean, but this time the sentiment is positive. Donald Trump has noticeably toned down his policy and statements regarding the trade war with China, which has significantly reduced market tension. Additionally, a certain impulse for local markets came from France, where a new government was formed at an express pace. The partial resolution of the political impasse reduces uncertainty and gives investors a small but noticeable reason for optimism.
Source: Bloomberg Terminal LP
We are experiencing noticeable gains across whole sectors. Among the leaders of growth in Europe today are companies from the automotive sector, pharmaceutical firms, and the broadly defined IT sector.
DE40 (D1)
Source: Xstation5
The chart shows that after bouncing off the levels of the last ATH, the index temporarily fell below the medium- and long-term trend lines (orange and red). However, a quick breakout above them confirmed their technical significance. Currently, the quotations are in the area of the FIBO 23.6% retracement of the last upward wave - which constitutes a key point of resistance/support. To maintain a positive scenario, it is necessary to defend the resistance around 24380 points, as its breach could initiate a correction towards 24100 points. The RSI indicator remains in the moderate valuation zone, suggesting neutral sentiment.
Company news:
SUESS MicroTec (SMHN.DE) — The semiconductor manufacturing company is up over 13% after receiving a positive recommendation from an investment bank.
Pharmaceutical companies have proposed supplies/discounts for the American healthcare system in exchange for tariff exemptions. Shareholders are mixed in their reactions. AstraZeneca (AZN.UK) is down about 1%. Sanofi (SNF.FR) is up about 0.5%, Novo Nordisk (NOVOB.DK) is down 2%.
PSI Software (PSAN.DE) - The software producer for energy manufacturers is up 34%, driven by the planned acquisition of the company by a private fund. This is a continuation of last week's movement, in which the company already rose by about 38%.
Despite few fundamental bases, automotive companies in Europe are experiencing a broad rebound. BMW(.DE) is up 1.7%, Stellantis (STLAM.IT) is up 2.3%.
Theon International (THEON.NL) - The Greek night vision manufacturing company announced the acquisition of shares in one of its French partners, with the stock price rising by over 8%.
US OPEN: "Green" Start to the Week on Wall Street
Indexes reduce gains after Bessent’s comments 🎙️
France on the Brink
China’s exports grow at the fastest pace since the start of the U.S. trade war 🔎
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
